Prenetics Global (NASDAQ:PRE) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Prenetics Global (NASDAQ:PRE) released its quarterly earnings data on Tuesday. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.11, Zacks reports. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 19.46%. The company had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.02 million.

Here are the key takeaways from Prenetics Global’s conference call:

• Record growth continued: Q2 revenue reached $46.5 million, up 29% sequentially and nearly fourfold year over year, while July revenue climbed to $20.9 million. IM8 reported 65% gross margins and its sixth consecutive record quarter.
• Guidance was raised materially: Full-year 2026 revenue guidance increased to $220 million-$230 million, and the company initiated 2027 guidance of at least $400 million. Management expects to exit 2026 at a revenue run rate above $300 million.
• Customer economics improved with scale: July brought a record 47,373 new customers at a $239 acquisition cost, roughly 21% below the Q2 average, alongside 140,000 active subscribers and approximately 87% recurring revenue. General Catalyst’s $1 billion growth financing is expected to fund about 70% of acquisition marketing.
• Expansion is planned but remains execution-dependent: IM8 expects to launch hydration in Q4 and gummies in early 2027, supported by clinical studies including trials at Mayo Clinic. Management emphasized that these products are not included in current guidance, so their contribution remains uncertain.
• Profitability is still developing: Q2 adjusted EBITDA was negative $19 million and net loss was $9 million, with losses largely driven by increased customer acquisition spending. Although management expects second-half adjusted EBITDA losses to narrow to $8 million-$12 million and adjusted free cash flow to remain positive, these measures depend partly on the General Catalyst financing structure.

Prenetics Global Price Performance

NASDAQ PRE opened at $18.76 on Thursday. The business has a 50 day simple moving average of $19.13 and a 200 day simple moving average of $18.88. Prenetics Global has a one year low of $7.18 and a one year high of $23.63. The stock has a market capitalization of $316.48 million, a P/E ratio of -4.51 and a beta of 0.26.

Hedge Funds Weigh In On Prenetics Global

Several institutional investors have recently added to or reduced their stakes in PRE. Jane Street Group LLC acquired a new position in shares of Prenetics Global during the 4th quarter valued at $1,302,000. Millennium Management LLC acquired a new stake in Prenetics Global in the fourth quarter worth $810,000. Marshall Wace LLP acquired a new stake in Prenetics Global in the fourth quarter worth $788,000. Goldman Sachs Group Inc. acquired a new position in shares of Prenetics Global during the fourth quarter valued at about $665,000. Finally, UBS Group AG raised its holdings in shares of Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after purchasing an additional 39,733 shares during the period. 25.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PRE has been the topic of a number of recent research reports. Benchmark raised their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen cut shares of Prenetics Global from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Prenetics Global currently has an average rating of “Moderate Buy” and a consensus price target of $34.25.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.